Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab adjunct to glaucoma surgery
ACTRN12614000375651Phase 4Not yet recruiting
- Sponsor
- John Landers
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bevacizumab in Glaucoma (2 arms), sponsored by John Landers. Primary endpoints: Proportion of patients with intraocular pressure at or below target on no medication and Proportion of patients with intraocular pressure at or below target with or without topical medication. Planned start Jun 2014; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
Glaucoma
Beyond the preview
Go deeper on ACTRN12614000375651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000375651.